Generex Is Granted a China Patent for Cancer Vaccine
ChinaBio Today submits:
Generex Biotechnology (NSDQ: GNBT) announced it has been granted a China patent for its Ii-Key peptide vaccine technology, a vaccine currently in US clinical trials to prevent a recurrence of breast cancer. Generex said the patent covers both its platform technologies and Ii-Key-containing drug development compounds. The patent was granted to Antigen Express, the Generex subsidiary that is developing the vaccine.
According to Generex, it is “actively seeking” either joint venture or licensing partnerships for the vaccine, and it has already begun discussions with several large pharmas.
Investing, Long Term Investment, stock market | admin March 3, 2010
RSS feed for comments on this post.
